



KIRTLAND AIR FORCE BASE INSTALLATION **COMMANDER'S DIRECTIVE**

Installation Commander's Directive #043B
UPDATED March 12, 2021

DIRECTIVE: COVID-19 Vaccine Preparation II

Vaccine eligibility:

- A. While under FDA Emergency Use Authorization, the COVID-19 Vaccine is strictly VOLUNTARY.
 - 1) Personnel may not be pressured in any way to receive the COVID-19 Vaccine
 - 2) Adverse personnel action may not be taken against any personnel based on their decision not to receive the COVID-19 Vaccine.
 - 3) Supervisors may make decisions regarding telework based on whether or not personnel have received the COVID-19 Vaccine. This should not be the sole consideration when making such a decision and should be balanced against all other relevant factors. DAF policy is to maximize telework whenever possible
 - 4) Civilian employees will not be asked if they have been vaccinated against COVID-19 unless the duty position they fill requires immunization.
- B. All Military, Civil Service, DoD Contractor employees, and Active Duty Dependent beneficiaries are eligible to receive the vaccine.
- C. Retirees, other eligible DoD beneficiaries, and all persons that work or reside on KAFB that are eligible to receive the influenza vaccine through our DoD occupational safety and health program may volunteer to receive the vaccine.

1. Prioritizing the Candidate Pool:

- A. Vaccine recipients will be prioritized based on supply and a tiered approach based on the most current DoD Vaccine Distribution Population Schema and HHQ directives/guidance:

REAL WORLD – REAL WORLD – REAL WORLD

- B. Units must poll 100% their population groups to determine volunteer status and create a candidate list using the COVID-19 Vaccination Roster Template (accessed via the COVID-19 Vaccination Planning SharePoint site (see paragraph 5 below)).
- 1) Prioritize the candidates within your unit based on critical need.
 - 2) Consider further sub-dividing your prioritized list into multiple waves to limit the number of persons vaccinated at one time. This wave approach will mitigate the potential impact of side effects that may develop within 48hours after vaccination.
 - 3) The Tier groups are predefined using DoD criteria however, if you have a person that requires a higher priority tier group, you may submit an Exception To Policy (ETP) with justification. Submit all ETP's to the Medical Control Center (MCC) for approval.
 - 4) Additional considerations:
 - A. All persons receiving the initial dose are expected to be available to receive the second dose 21 – 28 days after the initial, depending on vaccine brand given. Both doses must be the same brand.
 - B. Deploying members are expected to be on station and receive both the initial dose and the second dose (21-28 days after the initial dose) prior to departure.
 - C. If PCSing, personnel are expected to be available to receive both the initial dose and the second dose (21-28 days after the initial dose) prior to departure.
 - D. Pregnant and breastfeeding persons may volunteer as a candidate however, highly recommend consulting your OB/GYN before being vaccinated.
 - E. Pediatrics (children under the age of 18) may not volunteer as a candidate at this time.

4. The Vaccine:

- A. There are currently **three** COVID-19 vaccines granted emergency use and authorized and recommended by the FDA in the United States. The brand, quantity, and time frame for delivery is subject to availability and managed through the DoD distribution plan.
- B. The Pfizer Vaccine:
 - 1) Two dose series (day 0 and day 21)
 - 2) Mild side effects (fever, chills, body-aches, etc.) 4-48 hours after vaccination
 - 3) No significant adverse effects (44,000 trial subjects)
- C. The Moderna Vaccine:
 - 1) Two dose series (day 0 and day 28)
 - 2) Mild side effects (fever, chills, body-aches, etc.) 48 hours after vaccination
 - 3) No significant adverse effects (30,000 trial subjects)
- D. **Johnson & Johnson / Janssen**
 - 1) **Single dose vaccine**
 - 2) **Mild side effects (fever, chills, body-aches, etc.) within 48 hours after vaccination**
 - 3) **No significant adverse effects (45,000 trial subjects)**

ADDITIONAL INFORMATION:

- 1. The following ICDs remain in effect (please review ICDs for impact to your organization):
 - A. ICD 12, *Policy on Inbound Cargo and Packaging Sanitation Measures*
 - B. ICD 34, *Policy on Custodial "Special Clean" Requirements to Decon COVID-19*
 - C. ICD 45, *Implement HPCON Bravo+*
 - D. ICD 44C, *NM COVID-19 Impact*
- 2. This ICD Supersedes *ICD-043A Covid-19 Vaccination Preparation*

Installation Commander